PROTEOR Group Becomes One of the Largest Prosthetic Providers in the World
Proteor, a France-based international group specialized in prosthetic and orthotic solutions, has successfully completed its acquisition of American brand Freedom Innovations and the major part of the product portfolio from Ottobock. With this acquisition, the Proteor group is fueling its strategy to be a global leader in the international orthopaedic market. Proteor’s growth is accelerating with the addition of Freedom Innovation’s quality production, high-tech development, and well-known products: the microprocessor-controlled knee Plie3, the Kinnex and Kinterra ankles and the Agilix, DynAdapt, Sierra, Highlander and Pacifica carbon feet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201211005432/en/
Photo credit: Proteor
“I would like to thank all Freedom Innovations for their continued dedication, focus, hard work, and professionalism during this unpredictable time. We look forward to coming together as one family.” says Edouard Archambeaud, member of the Board of Directors of Proteor. “I would also like to thank Ottobock for working diligently towards a successful outcome and the FTC for their vote of confidence in our acquisition.”
The united organization counts more than 1,000 employees worldwide, more than doubling the US team, bolstered by four global innovation centers and a full product pipeline. The unique microprocessor products and added lower extremity prosthetics differentiate and expand the Proteor portfolio. The sales and support network is also strengthened, increasing contact with clinical customers.
“For all parties involved and especially for the employees of Freedom Innovations, the final solution is good news after several years of uncertainty and sets the future for Freedom Innovations under the roof of both Proteor and Ottobock”, says Philipp Schulte-Noelle, CEO of Ottobock. “I am especially grateful for the very constructive dialogue with the FTC in recent months and the engagement of Proteor.”
Proteor welcomes more than 100 members of the Freedom Innovations team in manufacturing, sales, marketing, R&D and clinical studies from Gunnison (Utah), Irvine (California) and Germany.
“I am thrilled with the energy and momentum this change brings,” said Matt Swiggum, President and CEO of Proteor USA. “It positions us for continued growth, building on our commitment to innovation and investment in our customers and their patients.”
Proteor’s journey centers on its customers. To uphold its focus on customer relationships and service, Proteor is working closely with Ottobock to facilitate a smooth and seamless transition of the Freedom Innovations business acquired by Proteor. Ottobock retains a substantial part of the prosthetic feet business with Kintrol foot-ankle prosthesis, the Maverick product family and other carbon feet.
We are Proteor
#HumanFirst
About Proteor:
Proteor, an independent family-company, was established more than 100 years ago headquartered in Dijon (France). Proteor operates within the O&P industry with three strategic pillars: software’s, components and custom-made devices. Thanks to continuous investments in innovation, many medical and scientific partnerships, and day to day cooperation with CPOs, Proteor enjoys a recognized expertise all over the O&P community.
For additional information visit: http://www.proteorusa.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201211005432/en/
Contact information
Contact media:
Sophie DESBOIS
sophie.desbois@proteor.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-225.1.2021 14:13:00 CET | Press release
Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005376/en/ AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2 (Photo: AchilleS Vaccines) The AchilleS antibody project ‘mAbCo19’ will now be further tested in the clinic, possibly leading to an emergency market authorization this summer. AchilleS is developing this new therapeutic in c
“Look for the WELL Health-Safety Seal” Public Awareness Campaign Launches, Featuring Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17 th U.S. Surgeon General Richard Carmona25.1.2021 14:00:00 CET | Press release
As the world continues to battle COVID-19 and communities strive to get back to business, it is more important than ever to raise confidence in the safety of buildings and shared spaces. Today, Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th Surgeon General Richard Carmona came together in a new integrated ad campaign to raise awareness about the importance of the WELL Health-Safety Rating, an evidence-based third-party designation to verify that a building or space has taken the necessary steps to prioritize the health and safety of their staff, visitors and other stakeholders. The ambassadors encourage people to look for buildings and spaces with the WELL Health-Safety seal on their windows or doors to feel more confident in their decision to go inside. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005216/en/ WELL Health-Safety Seal (Photo: Business
The Estée Lauder Companies Announces Supply Chain Leadership Updates25.1.2021 14:00:00 CET | Press release
TodayThe Estée Lauder Companies (NYSE:EL) announced that after nearly 13 years with the company, Gregory F. Polcer, Executive Vice President, Global Supply Chain, has made the decision to retire, effective July 1, 2021. He will be succeeded by Roberto Canevari, who will assume the role of Executive Vice President, Global Supply Chain, effective May 1, 2021. Roberto will report directly to Fabrizio Freda, President and Chief Executive Officer. Greg will work closely with Roberto over the next several months to support a smooth and successful transition. “Greg has led ELC’s Global Supply Chain with a great blend of strategic insight and innovative thinking,” said Mr. Freda. “He has evolved our Supply Chain organization into a truly integrated, state-of-the-art global network that touches all aspects of our business and drives tremendous value. He has also been instrumental in elevating and operationalizing our core principles of safety and sustainability, and has been an enthusiastic and
Everbridge Awarded Statewide Vaccine Distribution Deployment Across West Virginia; Everbridge Software Enables Governments, Hospitals and Businesses to Coordinate Rapid Delivery and Communications of COVID-19 Vaccine25.1.2021 13:30:00 CET | Press release
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced COVID-19 Shield™: Vaccine Distribution, an extension to its CEM platform offering risk insights, logistics awareness andvaccine appointment management to support the full spectrum of organizations that develop, manufacture, transport, distribute, regulate, and administer the coronavirus vaccine. The offering also provides governments with a single, unified platform to expedite vaccine coordination, communication and distribution for all residents, including vulnerable populations with special needs. Representing significant adoption for its vaccine distribution software, Everbridge announced the deployment of its CEM Platform to power the digital vaccination distribution system for a variety of municipalities and organizations, including the entire state population of West Virginia, and the County of Sarasota, Florida, among others. This press release features multimedia. View the ful
Velodyne Lidar LIVE! Webinar Series Explores Autonomy in Smarter Cities, Caves, Airports and Disaster Response25.1.2021 13:00:00 CET | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a new digital learning series called Velodyne Lidar LIVE! that begins January 28, 2021 at 1:00 p.m. PST. The series kicks off with a conversation featuring Dr. Stefan Hrabar, CEO of Emesent, on how to address autonomous exploration in challenging inaccessible environments such as caves, civil construction works, telecommunications infrastructure and disaster response environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005104/en/ The Velodyne Lidar LIVE! digital learning series examines what’s happening in lidar and mobility to build a safer, more intelligent future. (Graphic: Velodyne Lidar, Inc.) To register for episodes of the free Velodyne Lidar LIVE! webinar series visit: https://velodynelidar.com/events/. Velodyne Lidar LIVE! looks at industry developments regarding the advancement of safer mobility and smarter autonomy. The 45-minute webinars fea
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT ® (Siltuximab for Injection) in China25.1.2021 13:00:00 CET | Press release
EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT® (siltuximab for injection) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Siltuximab is a monoclonal antibody approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). iMCD is a rare, life-threatening and debilitating condition of the lymph nodes and related tissues. Siltuximab is listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005360/en/ “The BLA acceptance of siltuximab for review, an importan
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-225.1.2021 12:37:00 CET | Press release
Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005376/en/ AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2 (Photo: AchilleS Vaccines) The AchilleS antibody project ‘mAbCo19’ will now be further tested in the clinic, possibly leading to an emergency market authorization this summer. AchilleS is developing this new therapeutic in c